The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.
New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset.
RA'ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), an innovative medical technology company valued at $15.7 million, has announced positive initial results from its collaboration ...
Inspira Technologies OXY B.H.N. announced positive initial results from collaboration with Ennocure MedTech to develop ...
Daniels says the shortage of brand name drugs like glucagon-like peptide-1 (GLP-1) medications to treat diabetes and obesity ...
The saline manufacturing company submitted that it had gotten a clean chit from the central laboratory after sending the state's saline for testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback